Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ET140202-T Cell with TAE or Sorafenib in Advanced Liver Cancer
NCT03965546Phase 1Unknown
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- May 2019
- Primary completion
- Jun 2021
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of et1402l1-artemis t cells in hepatocellular carcinoma (HCC) (3 arms), sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: Frequency of ARTEMIS T cell treatment-related adverse events at 2 years. Status: unknown.
02
Drugs
et1402l1-artemis t cells
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03965546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03965546.